636 related articles for article (PubMed ID: 16950362)
1. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.
Bourhis J; Overgaard J; Audry H; Ang KK; Saunders M; Bernier J; Horiot JC; Le Maître A; Pajak TF; Poulsen MG; O'Sullivan B; Dobrowsky W; Hliniak A; Skladowski K; Hay JH; Pinto LH; Fallai C; Fu KK; Sylvester R; Pignon JP;
Lancet; 2006 Sep; 368(9538):843-54. PubMed ID: 16950362
[TBL] [Abstract][Full Text] [Related]
2. Hyperfractionated or accelerated radiotherapy for head and neck cancer.
Baujat B; Bourhis J; Blanchard P; Overgaard J; Ang KK; Saunders M; Le Maître A; Bernier J; Horiot JC; Maillard E; Pajak TF; Poulsen MG; Bourredjem A; O'Sullivan B; Dobrowsky W; Andrzej H; Skladowski K; Hay JH; Pinto LH; Fu KK; Fallai C; Sylvester R; Pignon JP;
Cochrane Database Syst Rev; 2010 Dec; 2010(12):CD002026. PubMed ID: 21154350
[TBL] [Abstract][Full Text] [Related]
3. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis.
Lacas B; Bourhis J; Overgaard J; Zhang Q; Grégoire V; Nankivell M; Zackrisson B; Szutkowski Z; Suwiński R; Poulsen M; O'Sullivan B; Corvò R; Laskar SG; Fallai C; Yamazaki H; Dobrowsky W; Cho KH; Beadle B; Langendijk JA; Viegas CMP; Hay J; Lotayef M; Parmar MKB; Aupérin A; van Herpen C; Maingon P; Trotti AM; Grau C; Pignon JP; Blanchard P;
Lancet Oncol; 2017 Sep; 18(9):1221-1237. PubMed ID: 28757375
[TBL] [Abstract][Full Text] [Related]
4. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
[TBL] [Abstract][Full Text] [Related]
5. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial.
Overgaard J; Mohanti BK; Begum N; Ali R; Agarwal JP; Kuddu M; Bhasker S; Tatsuzaki H; Grau C
Lancet Oncol; 2010 Jun; 11(6):553-60. PubMed ID: 20382075
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
Budach W; Hehr T; Budach V; Belka C; Dietz K
BMC Cancer; 2006 Jan; 6():28. PubMed ID: 16448551
[TBL] [Abstract][Full Text] [Related]
7. Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of locoregionally advanced head and neck squamous cell carcinoma: An adjusted indirect comparison meta-analysis.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Head Neck; 2015 May; 37(5):670-6. PubMed ID: 24596112
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
[TBL] [Abstract][Full Text] [Related]
9. Altered and conventional fractionated radiotherapy in locoregional control and survival of patients with squamous cell carcinoma of the larynx, oropharynx, and hypopharynx.
Krstevska V; Crvenkova S
Croat Med J; 2006 Feb; 47(1):42-52. PubMed ID: 16489696
[TBL] [Abstract][Full Text] [Related]
10. Hyperfractionated accelerated radiotherapy alone and with concomitant chemotherapy to the head and neck: treated within and outside of randomized clinical trials.
Hehr T; Classen J; Schreck U; Glocker S; Bamberg M; Budach W
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1424-30. PubMed ID: 15050319
[TBL] [Abstract][Full Text] [Related]
11. Preoperative hyperfractionated accelerated radiotherapy and radical surgery in advanced head and neck cancer: a prospective phase II study.
Lindholm P; Valavaara R; Aitasalo K; Kulmala J; Laine J; Elomaa L; Sillanmäki L; Minn H; Grénman R
Radiother Oncol; 2006 Feb; 78(2):146-51. PubMed ID: 16307813
[TBL] [Abstract][Full Text] [Related]
12. Improved results with accelerated hyperfractionated radiotherapy of advanced head and neck cancer.
Leborgne F; Zubizarreta E; Fowler J; Ortega B; Mezzera J; Deus JL; Leborgne JH
Int J Cancer; 2000 Apr; 90(2):80-91. PubMed ID: 10814958
[TBL] [Abstract][Full Text] [Related]
13. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.
Huguenin P; Beer KT; Allal A; Rufibach K; Friedli C; Davis JB; Pestalozzi B; Schmid S; Thöni A; Ozsahin M; Bernier J; Töpfer M; Kann R; Meier UR; Thum P; Bieri S; Notter M; Lombriser N; Glanzmann C
J Clin Oncol; 2004 Dec; 22(23):4665-73. PubMed ID: 15534360
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.
Bentzen SM; Atasoy BM; Daley FM; Dische S; Richman PI; Saunders MI; Trott KR; Wilson GD
J Clin Oncol; 2005 Aug; 23(24):5560-7. PubMed ID: 16110017
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
16. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Budach V; Stromberger C; Poettgen C; Baumann M; Budach W; Grabenbauer G; Marnitz S; Olze H; Wernecke KD; Ghadjar P
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):916-24. PubMed ID: 25670541
[TBL] [Abstract][Full Text] [Related]
17. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
18. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study.
Poulsen MG; Denham JW; Peters LJ; Lamb DS; Spry NA; Hindley A; Krawitz H; Hamilton C; Keller J; Tripcony L; Walker Q
Radiother Oncol; 2001 Aug; 60(2):113-22. PubMed ID: 11439206
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.
Pignon JP; Bourhis J; Domenge C; Designé L
Lancet; 2000 Mar; 355(9208):949-55. PubMed ID: 10768432
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
